Biomark Diagnostics Inc. (FRA:20B)

Biomark Diagnostics Statistics

Total Valuation

FRA:20B has a market cap or net worth of EUR 37.20 million. The enterprise value is 36.85 million.

Market Cap	37.20M
Enterprise Value	36.85M

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

FRA:20B has 105.09 million shares outstanding. The number of shares has decreased by -84.66% in one year.

Current Share Class	105.09M
Shares Outstanding	105.09M
Shares Change (YoY)	-84.66%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	12.49%
Owned by Institutions (%)	n/a
Float	48.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	652.61
PB Ratio	117.89
P/TBV Ratio	117.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-34.90
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-28.93

Financial Position

The company has a current ratio of 1.20, with a Debt / Equity ratio of 1.40.

Current Ratio	1.20
Quick Ratio	1.20
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-0.35
Interest Coverage	-39.96

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-81.70%
Return on Invested Capital (ROIC)	-152.63%
Return on Capital Employed (ROCE)	-218.42%
Weighted Average Cost of Capital (WACC)	3.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +160.29% in the last 52 weeks. The beta is -0.22, so FRA:20B's price volatility has been lower than the market average.

Beta (5Y)	-0.22
52-Week Price Change	+160.29%
50-Day Moving Average	0.32
200-Day Moving Average	0.23
Relative Strength Index (RSI)	52.54
Average Volume (20 Days)	525

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:20B had revenue of EUR 57,005 and -1.06 million in losses. Loss per share was -0.01.

Revenue	57,005
Gross Profit	57,005
Operating Income	-1.22M
Pretax Income	-1.06M
Net Income	-1.06M
EBITDA	-1.21M
EBIT	-1.22M
Loss Per Share	-0.01

Balance Sheet

The company has 798,941 in cash and 442,136 in debt, with a net cash position of 356,805 or 0.00 per share.

Cash & Cash Equivalents	798,941
Total Debt	442,136
Net Cash	356,805
Net Cash Per Share	0.00
Equity (Book Value)	315,575
Book Value Per Share	0.00
Working Capital	151,279

Cash Flow

In the last 12 months, operating cash flow was -882,715 and capital expenditures -390,819, giving a free cash flow of -1.27 million.

Operating Cash Flow	-882,715
Capital Expenditures	-390,819
Depreciation & Amortization	10,043
Net Borrowing	214,243
Free Cash Flow	-1.27M
FCF Per Share	-0.01

Margins

Gross Margin	100.00%
Operating Margin	-2,145.49%
Pretax Margin	-1,852.08%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:20B does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	84.66%
Shareholder Yield	84.66%
Earnings Yield	-2.84%
FCF Yield	-3.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:20B has an Altman Z-Score of -3.64 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.64
Piotroski F-Score	2